- Home
- SGHT
SGHT
Sight Sciences Inc.
as 10-22-2024 3:30pm EST
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 304.4M | IPO Year: | 2021 |
| Target Price: | $7.20 | AVG Volume (30 days): | 144.8K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $8.45 | Next Earning Date: | 11-07-2024 |
| Revenue: | $79,395,000 | Revenue Growth: | -2.60% |
| Revenue Growth (this year): | 3.39% | Revenue Growth (next year): | 11.43% |
Stock Insider Trading Activity of Sight Sciences Inc. (SGHT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Badawi David | SGHT | Chief Technology Officer | Oct 2 '24 | Sell | $5.99 | 3,167 | $18,957.66 | 1,756,481 | |
| Badawi Paul | SGHT | President and CEO | Oct 2 '24 | Sell | $5.99 | 12,727 | $76,183.82 | 5,725,433 | |
| HAYDEN JEREMY B. | SGHT | Chief Legal Officer | Oct 1 '24 | Sell | $6.08 | 4,878 | $29,658.24 | 158,687 | |
| Bauerlein Alison | SGHT | Chief Financial Officer | Oct 1 '24 | Sell | $6.08 | 10,130 | $61,590.40 | 392,555 | |
| Park Sam Boong | SGHT | Chief Operating Officer | Oct 1 '24 | Sell | $6.08 | 3,403 | $20,690.24 | 254,826 |
Latest Sight Sciences Inc. News
SGHT Breaking Stock News: Dive into SGHT Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024
MT Newswires
9 days ago
Sight Sciences' TearCare Treatment Improves Symptoms of Dry Eye Disease in Trial
GlobeNewswire
9 days ago
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial
Simply Wall St.
23 days ago
Institutional investors own a significant stake of 34% in Sight Sciences, Inc. (NASDAQ:SGHT)
The Fly
2 months ago
AmEx downgraded, Texas Instruments upgraded: Wall Street's top analyst calls
GlobeNewswire
2 months ago
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Thomson Reuters StreetEvents
3 months ago
Q2 2024 Sight Sciences Inc Earnings Call
Zacks
3 months ago
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Compare SGHT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGHT Sight Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.